Clinical Trials

Title   A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Pl
Description   To assess if treatment with rovalpituzumab tesirine improves objective response rate (ORR) and overall survival (OS) compared to topotecan in subjects with advanced or metastatic DLL3high SCLC who have first disease progression during or following front-line platinum based chemotherapy.Therefore, exploration of new therapies in second line SCLC is warranted, with the goals of extending disease control and improving overall survival.
IRB Number   17-080
Treatment   Oncology - Lung Cancer
Status   Active
Principal Name   Moh'd Khushman, , MD
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us